

PARTICIPATING COMPANIES



4M Therapeutics, Skillman, New Jersey

4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative diseases. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaboration between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics. The Company's pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer's disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net.

4mtx.net

Pablo Lapuerta: pablo@4mtx.net



Aikynetix, Houston, Texas

AiKynetix is a start-up revolutionizing human motion analytics with AI-powered tools that deliver lab-quality motion analysis through only a smartphone and a 30-second video upload. It's fast, affordable, and 95% accurate to marker-based systems. Our platform provides real-time feedback across range of motion, running, jumping, and weightlifting. With AiKynetix, you can offer smarter, data-driven insights to your clients in fitness and rehabilitation—enhancing both performance and satisfaction.

aikynetix.com

Anton Galvas: anton@aikynetix.com



Anvil Diagnostics, Cambridge, Massachusetts

Anvil Diagnostics is developing simple blood tests to improve the management of invasive infections in hospitals. Detecting pathogens guides treatment but relies on culture which is slow and error prone. Spun out of Rice University, Anvil's proprietary chemistry and software enables existing PCR hardware to detect nearly all pathogens and major resistance genes in 3h without culture. This capital-efficiency allowed Anvil to progress from concept to initial patient data and three letters of intent from leading institutions in less than a year. Anvil's core technologies can be applied across a range of patient indications in the fast-growing liquid biopsy market.

anvildiagnosics.com

Pavan Kota: pavan@anvildiagnosics.com



Autoimmunity BioSolutions, Houston, Texas

Autoimmunity BioSolutions is a Houston-based, seed-stage biotech developing a next-generation, immuno-corrective therapy for treatment of autoimmune diseases to restore normal immune function. This therapy is targeted to a genetically-defined subpopulation of autoimmune disease patients marked by a highly prevalent SNP associated with increased risk and severity of various autoimmune diseases. The SNP drives the autoimmune pathology by enhancing the expression of the soluble interleukin 7 receptor (sIL7R) isoform, which enhances the activation of autoreactive T cells and their conversion to autoreactive memory T cells. The therapy is a monoclonal antibody that corrects the upregulated sIL7R to restore immune homeostasis.

abstherapeutics.com

Gaddiel Galarza-Munoz: gaddiel@abstherapeutics.com

PARTICIPATING COMPANIES



Avesta76 Therapeutics, Inc., Los Angeles, California

Avesta76 Therapeutics is a preclinical oncology company that is developing novel anti-cancer therapeutics. Our therapeutics can restore the tumor suppressive function of p53, and by doing so, can completely regress tumors with no negative side effects. We have demonstrated our remarkable results in more than 12 types of cancer in animal models, and we are primed to begin clinical trials in 8-12 months.

avesta76.com

Ian Morrison: akash@avesta76.com



AyuVis Research, Inc., Fort Worth, Texas

AyuVis is a clinical-stage pharmaceutical company developing a proprietary immunomodulation technology based on small-molecule drug designs that facilitate and modulate a unique profile of immune cells. The compounds quieten hyperinflammation and simultaneously balance the immune response with adequate disease clearance and specific tissue repair. Our lead compound is entering clinical trials to prevent pediatric neonatal lung diseases for which there are no FDA-approved therapies, or ineffective existing therapies are not effective. The next step in the pipeline includes the development of effective anti-viral therapy and effective vaccine adjuvant where current vaccines are failing.

ayuvis.com

Suchi Acharya: sacharya@ayuvis.com




Barricade Therapeutics, Fort Worth, Texas

Barricade Therapeutics is a Dallas-based drug development company advancing its clinical candidate, BT-1501, to a First-in-Human clinical trial in metastatic APCmutant colorectal cancer patients during 1H2025. The Company was founded by experienced pharma entrepreneurs who have designed, developed and advanced drugs through the regulatory process. Barricade has licensed its EBP inhibitor technology from UT Southwestern Medical Center. Additionally, their drugs, known as "TASINs," have demonstrated anti-tumor activity in cancers such as neuroblastomas and Burkitt's Lymphoma and remyelinate nerve cells in demyelinating diseases such as Multiple Sclerosis. Barricade holds issued composition of matter and method of use patents for their drugs.

BarricadeTherapeutics.com

Neil Thapar: nthapar@barricadetherapeutics.com



CASE45

Case45, London, United Kingdom

Develop and commercialize pan-cancer prognostic tests using unique integration of tumor evolution and AI, offering 100x faster and 40% more accurate solutions, starting with unmet needs for breast and lung cancers.

case45.com

Khalid AbdulJabbar: khalid@case45.com

PARTICIPATING COMPANIES



CorInnova, Inc., Houston, Texas

CorInnova is developing a minimally invasive non-blood contacting biventricular cardiac assist device for treating acute heart failure patients that eliminates the many adverse events associated with existing cardiac assist devices due to blood contact. The device, initially for the fast-growing short-term cardiac assist market (up to 5 days' use), will expand the addressable market by \$5B+ by treating 50% of patients who cannot use existing devices and save up to 150,000 lives/year. The self-expanding, pneumatically driven device deploys within the pericardial sac and surrounds both ventricles. It gently compresses the heart to increase output in synchrony with the heartbeat.

corinnova.com

William Altman: william.altman@corinnova.com



Cx Precision Medicine, Fort Worth, Texas

CxPM's blood-based NeuroFirst Memory test is the first and only blood-based biomarker test to help PCPs triage which patients with memory complaints are highly unlikely to have Alzheimer's and Related Dementias and should be evaluated for other causes and which should be referred for a dementia evaluation. NeuroFirst Memory decreases unnecessary referrals to specialists and increases diagnostic accuracy. The test is licensed from the University of North Texas Health Science Center, which has received over \$250M to develop the underlying technology. NeuroFirst Memory will be validated as an LDT in 4Q2024 and launch selectively in 1Q2025. NeuroFirst Parkinson's test follows.

cxprecisionm.com

Danguole Altman: daltman@cxprecisionm.com



Cytecom, Coventry, West Midlands, United Kingdom

Quick and accurate diagnosis and treatment of blood infections are crucial to prevent the progression to life-threatening sepsis, which affects 49 million people and causes 11 million deaths globally each year. Currently, identifying the right antibiotics takes 2-3 days, during which patients' conditions can worsen. Cytecom's innovative technology, powered by cutting-edge optical electrophysiology, aims to reduce this time to mere minutes. This advancement enables doctors to prescribe targeted antibiotics up to two days faster, potentially transforming clinical microbiology diagnostic labs, reducing patients' hospital stays, and providing significant cost savings for healthcare systems.

cytecom.co.uk

Magdalena Karlikowska: m.karlikowska@cytecom.co.uk



Diakonos Oncology, Houston, Texas

Diakonos Oncology is developing its groundbreaking "double-loaded" dendritic cell therapy for aggressive and hard-to-treat cancers such as glioblastoma (GBM). Treating 16 newly diagnosed patients in its Phase I trial, Diakonos' DOC1021 demonstrated a 93% 12-month survival rate compared to a 50% - 60% 12-month survival rate expected with the standard of care. Diakonos is now preparing to launch its Phase II trial at leading academic centers across the US. Diakonos is opening a Series A funding round to support this critical next step, following the recent success of its oversubscribed Seed Round, which raised \$11.4M.

diakonsoncology.com

Jay Hartenbach: j.hartenbach@diakonsoncology.com

PARTICIPATING COMPANIES



Direct Biologics, Austin, Texas

Direct Biologics is a late-stage biotechnology company focused on shepherding the next paradigm shift in medicine with its new platform of potential therapeutics called extracellular vesicle (EV). The platform consists of a form of stem cell therapy without the cells, DNA or mitochondria. Our mission is to drastically improve the standard of care for patients globally by harnessing the natural power of regenerative EV technology. Our value proposition is being the first MSC derived EV therapeutic candidate in Phase 3 clinical development for acute respiratory distress syndrome (ARDS) through expertise in manufacturing, R&D, quality assurance, clinical operations and regulatory affairs. Globally, ARDS has a 50% mortality rate with no current approved therapeutic drug available for the disease. In the US, ARDS represents approximately 15% of all ICU admissions.

directbiologics.com

Bruce Middleton: bruce@directbiologics.com



Eisana Health, Spring, Texas

Eisana Health is preventing side effects from cancer treatment, starting with a novel cooling system to prevent painful and incurable nerve damage caused from many chemotherapy drugs. This nerve damage significantly decreases quality of life and payors are spending an average of \$17k per patient, per year, dealing with symptoms. In a recent study, nerve damage was reduced by 55% with cooling. Unfortunately, there's no easy way to do it. Patients are struggling with ice cold solutions, designed for injury or rehabilitation. We are incorporating extensive input from oncologists, nurses, and patients, and are funded by the National Cancer Institute.

eisana.com

Carole Spangler Vaughn: carole@eisana.com



EXoPERT, Seoul, South Korea

EXoPERT is developing liquid biopsy based multi-cancer early detection platform. In order to demonstrate high accuracy, low price, and simple process; exosomes are selected as our target, Raman spectroscopy is used to obtain all information about every single molecules contained in the exosomes, and finally those information are analyzed by machine-learning model.

exopert.com

Yeonho Choi: yeonhochoi@exopert.com



Flat Medical, Taipei City, Taiwan

Flat Medical is a medtech company providing safety solutions for clinical interventions, now has FDA cleared and CE marked EpiFaith and EpiFaith CV, safety solutions for epidural and central line placements. The company is now commercializing the products in the U.S., Europe, Japan and Taiwan, with its own clinical service team and partnering specialty distributors and major branding partners including market leaders like B Braun. The company is now raising its Series D round, a growth round to fuel its global growth and to support its continuous R&D and corporate development activities.

flatmedical.com

Matthew Lee: matt@lexnovia.studio

PARTICIPATING COMPANIES



Foxo Technology Pty Ltd, Houston, Texas

Foxo is a Health Communication Orchestrator offering HIPAA-compliant, interoperable channels that reach anyone in healthcare without requiring external recipients to have an account. It supports omni-channel inbound/outbound, integrates with EHRs, MS Teams, and AI scribes, and enables efficient, secure communication, helping address workforce challenges. Selected for the 2024 Texas Medical Center Innovation (TMCi) Global HealthTech cohort, Foxo is also now a Microsoft partner, enhancing global healthcare communication.

foxo.com

Mani Sahihi: mani@foxo.com



Greenwich LifeSciences, Stafford, Texas

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating the safety and efficacy of GP2, an immunotherapy to prevent metastatic breast cancer recurrences after completion of adjuvant trastuzumab based treatment. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers. Flamingo-01 is currently expanding into Europe with up to 150 sites globally.

greenwichlifesciences.com

Snehal Patel: snehal.patel@greenwichlifesciences.com



Heartfelt Technologies, Cambridge, United Kingdom

Heartfelt Technologies has produced a passive, AI enabled, remote monitoring device designed for non-adherent heart failure patients. By measuring foot swelling as a patient walks past the device in their home we have shown in UK trials that we get 11x more data than standard care and predict a hospitalization a median of 13 days in advance, giving time for the medical system to intervene.

hftech.org

Joe Nelson: joe@hftech.org



Ictero Medical, Houston, Texas

Ictero is a medical device startup developing the CholeSafe System, the first minimally invasive cryoablation solution for gallbladder disease. Targeting elderly and high-risk patients who are not candidates for traditional surgery, CholeSafe defunctionalizes the gallbladder in place, offering a safer alternative to surgery. The company was born out of the Texas Medical Center's Biodesign program and is headquartered in Houston, leveraging the city's vast clinical network and startup resources. With a focus on innovation, Ictero combines cutting-edge engineering, clinical expertise, and regulatory experience to address a significant unmet need in gastrointestinal disease treatment.

icteromedical.com

Matthew Nojoomi: matthew.nojoomi@icteromedical.com

PARTICIPATING COMPANIES



Immatics, Stafford, Texas

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

immatics.com

Harpreet Singh



ImmunoGenesis, Houston, Texas

ImmunoGenesis is a clinical-stage biotechnology company focused on transforming immuno-oncology. The company's lead product, IMGS-001, is a potent PD-1 pathway targeting agent specifically engineered for immune-excluded tumors, which account for over 50% of all cancers. IMGS-001 is a cytotoxic, PD-L1/PD-L2 dual-specific antibody designed to promote the rejection of immune-excluded cancers by remodeling the tumor microenvironment (TME). PD-L1 and PD-L2 (PD-1 ligands) are widely expressed on immunosuppressive cells in the TME as well as by the tumor. IMGS-001 can kill these cells expressing PD-L1 and/or PD-L2 and also block the PD-1 pathway inhibitory signal. This multi-tasking mechanism gives IMGS-001 the potential to drive a >30% response rate as a monotherapy in immune-excluded tumors, a significant improvement over the current PD-1 inhibitors that have response rates below 5%. As a result, IMGS-001 can become a market leader in a \$100 billion market. The drug is currently in a Phase 1 a/b clinical trial with initial data available by mid-2025.

immunogenesis.com

James Barlow: james.barlow@immunogenesis.com



Informuta, San Diego, California

Our platform technology uses machine learning to analyze bacterial DNA to accurately guide effective treatment for difficult infections and, for the first time, predict if infections will become drug-resistant before it happens, all while reducing turnaround time by 80% compared to standard of care.

Informuta.com

Kalen Hall: kalenhall@informuta.com



INIA Biosciences, Boston, Massachusetts

INIA Biosciences is revolutionizing immunosuppression by developing a non-invasive at-home wearable ultrasound-based technology targeting the splenic nerve for the activation of the cholinergic anti-inflammatory pathway. The activation of this mechanism has an advantage over biologics and immunosuppression drugs that it does not result in several side-effects, while it also activates pro-resolving mediators (SPMs) that are crucial in resolving inflammation and repairing tissue, allowing the immune system to return to its balanced state. INIA is leveraging the long-established safety and effectiveness of ultrasound that has been utilized for centuries and delivering it as medical device therapy for patients with moderate/severe psoriasis.

iniabiosciences.com

Dragana Savic: dragana@iniabio.com

PARTICIPATING COMPANIES



Innotive Diagnostics, Bath, Somerset, United Kingdom

Innotive Dx is developing a revolutionary, point of care, rapid bacterial infection diagnostic system. Initially targeting urinary tract infections (UTIs). UTIs account for 400 million infections and almost 25% of all antibiotic prescriptions globally each year, however, diagnostics have changed little in 100 years due to the low cost of goods required to be commercially successful while still providing the 3 critical data points (enumeration, bacterial ID and antimicrobial sensitivity) to accurately diagnose a UTI. Innotive Dx can provide the 3 critical data in less than 60 minutes at an expected cost of goods of <\$4.

innotivedx.com

James Mainwaring: james.mainwaring@innotivedx.com



Loop Robots, Houston, Texas

Loop Robots automates disinfection with intelligent robot SAM-UVC to make medical-grade disinfection faster, safer, and digitally auditable. SAM helps Environmental Services Staff in healthcare, biotech, pharma, and medtech by automating the error-prone, time-consuming, and challenging disinfection job. SAM uses powerful and clean UV light to disinfect, so no harmful chemicals are needed anymore. SAM is safe and certified, and several academic hospitals and cGMP production facilities have verified its clinical efficacy in killing microorganisms. Research shows that automated room disinfection using UV-C light reduces hospital-acquired infections by 40%.

looprobots.com

Mark van de Vrede: mark.vandevrede@looprobots.com



Luminary Therapeutics, Inc., Minneapolis, Minnesota

Luminary Therapeutics is revolutionizing allogeneic CAR-T therapy by pioneering a triple receptor CAR design aimed at surpassing the efficacy of conventional single receptor CD19 treatments for autoimmune diseases. Additionally, our innovative split co-stimulatory CAR design is poised to propel the industry forward in addressing solid tumors. Currently, Luminary is conducting three Phase I First-in-Human trials utilizing an autologous format to establish safety and detect early indications of efficacy.

luminarytx.com

Jeff Liter: j.liter@luminarytx.com



LunOSA, Somerville, Massachusetts

LunOSA is unlocking the obstructive sleep apnea treatment paradigm by developing the first ever self-expanding neural electrode array that self-anchors. Currently, patients undergo an invasive face surgery to be implanted with a hypoglossal nerve stimulator and hope that it works (efficacy near 48%). BRELLA system enables face-surgery-free needle implant and a try-before-you-buy technique that ensures that only responders get implanted. LunOSA takes minimally invasive to the max with MANTA, a custom designed generator that 3x smaller than existing implants. LunOSA is poised to upset the \$10B OSA market and has FDA IDE approvals and animal studies.

lunosasleep.com

Bryan McLaughlin: bryan@lunosasleep.com

PARTICIPATING COMPANIES



March Biosciences, Houston, Texas

March Biosciences is a clinical stage cell therapy company addressing challenging diseases with novel targets. Our lead asset is moving into a Phase 2 clinical trial for relapsed and refractory T cell lymphoma, a disease with an incredibly poor prognosis under current standard of care. We are developing a pipeline of innovative therapies to expand our impact beyond T cell malignancies into autoimmune and novel oncology targets.

march.bio

Sarah Hein: sarah@march.bio



Mongoose Bio, Inc., Houston, Texas

Mongoose Bio, Inc. is an innovative clinical-stage biopharmaceutical company at the forefront of precision oncology, pioneering first-in-class T cell receptor T cell (TCR-T) therapies. By leveraging our proprietary antigen discovery pipeline and advanced memory T cell reprogramming technology, we achieve unparalleled coverage of both common and rare solid tumors, delivering sustained immunoprotection. We integrate Generative Artificial Intelligence (Gen AI) to enhance our antigen discovery and T cell engineering processes, optimizing therapeutic efficacy and patient outcomes.

mongoosebio.com

Neil Warma: neil@mongoosebio.com



Neurovalens, Middletown, Delaware

Neurovalens has developed non-invasive technology that is worn at home for 30 minutes per day, and has been designed to safely stimulate neurons in the brainstem in a way that treats disease. Currently, Neurovalens has received two FDA clearances for both Modius Sleep (A treatment for chronic insomnia) and Modius Stress (a treatment for generalized anxiety disorder). A de novo approval for PTSD is expected in 2025. In parallel, Neurovalens is also exploring a range of devices to treat metabolic disease such as obesity and type 2 diabetes.

neurovalens.com

Jason McKeown: jason.mckeown@neurovalens.com



NKILT Therapeutics, Houston, Texas

NKILT has engineered Natural Killer Cells to express a targeting agent called a CIR that directs targeting killing of tumors that express the protein HLA-G in its many isoforms. HLA-G is expressed in about 50% of tumors and in the immunosuppressive tumor microenvironment across indications. The off-the-shelf CIR-NK cell therapy is also engineered to enhance cytotoxicity and persistence to provide wide patient access to therapy with reduced cost and increased safety relative to autologous (patient derived) CAR-T cell therapies.

nkilt.com

Henri Bayle: henri.bayle@nkilt.com

PARTICIPATING COMPANIES



OmniNano Pharmaceuticals, LLC, Houston, Texas

OmniNano Pharmaceutical's patented nano-drug delivery platform technology enables simultaneous co-delivery of multiple therapeutic agents, designed specifically to treat solid tumors. Our lead drug candidate, ONP-001, consists of novel polymeric micelles encapsulating two drug compounds: one a clinically validated and FDA-approved chemotherapeutic and the other a well-studied tumor stroma modulator. Simultaneous delivery of these two drugs enhances drug delivery efficiency to the tumor, reduces cancer stem cells, and kills proliferating cells, significantly increasing median overall survival in multiple preclinical pancreatic cancer (PDAC) models. Our goal is to significantly improve patient outcomes, while reducing treatment limiting toxicity, starting with pancreatic cancer.

omninanopharma.com

Leslie Sloan: leslie.sloan@omninanopharma.com



Opsin Biotherapeutics, Inc., Bedford, Texas

Opsin Biotherapeutics is a pain management company focused on providing a novel alternative for chronic pain. Greater than 100M Americans suffer from chronic pain. In 2016, 11.5M people misused prescription opioids leading to 42,000 deaths and \$504B in economic costs. Our solution to access the 34,000 patients and \$7B neuromodulation pain market is to provide an alternative to electrical stimulation by using an episomal gene therapy using light to activate an in-situ drug (opsin) to inhibit pain transmitting neurons. Opsin Biotherapeutics has an experienced management team and advisory board that will bring this technology through regulatory approval and commercial success.

opsinbio.com

Bob Benkowski: bob.benkowski@opsinbio.com



Oxford Medical Products, Witney, Oxfordshire, United Kingdom

Oxford Medical Products, a UK-based biotech company, have developed a co-polymer platform technology with two primary applications: 1) a non-invasive and non-pharmacological obesity treatment and 2) a gastroretentive drug delivery system. Our lead asset, Sirona, is an oral pill that rapidly swells in the stomach, mechanically suppressing appetite. Sirona has successfully completed phase 1 and 2 trials and has demonstrated excellent safety and tolerability. This makes Sirona ideally suited for long-term use in helping overweight and obese individuals effectively manage their weight. It also offers a solution to prevent weight regain in those transitioning off GLP-1 medications.

oxfordmedicalproducts.com

Camilla Easter: camilla.easter@oxfordmedicalproducts.com



Parnassus Medical Systems, Houston, Texas

Parnassus Medical Systems, based in Houston, is transforming drug discovery and personalized healthcare with advanced AI and biomedical informatics. We focus on repositioning existing drugs and delivering innovative diagnostic solutions tailored to each patient, making treatments safer, faster, and more accessible. Our upcoming product, DeepStroke, is an AI-powered stroke screening system designed to prevent up to 3 hours of brain damage by reducing misdiagnosis and treatment delays.

parnassusmed.com

Patrick Sui: psui@parnassusmed.com

PARTICIPATING COMPANIES

The logo for PHIOGEN, featuring the word "PHIOGEN" in a bold, sans-serif font. The "PHIO" is in dark blue and "GEN" is in a teal color. A small trademark symbol (TM) is located to the upper right of the word.

PHIOGEN, Houston, Texas

PHIOGEN has developed a world-first biotechnology platform designed to generate next-generation live biotherapeutics (LBPs) to tackle the global threat of drug-resistant and recurrent bacterial infections. PHIOGEN is creating breakthrough antimicrobial solutions by using state-of-the-art capture technology and human-like model systems that mimic the complexity of real infections by selecting hyper-functional bacteriophages that target bacterial vulnerabilities and utilize proprietary machinery to drive evolutionary changes that overcome resistance.

phiogenpharma.com

Amanda Burkardt: amanda@phiogenpharma.com



QV Bioelectronics, Nether Alderley, Cheshire, United Kingdom

QV Bioelectronics is developing a first of its kind implantable medical device to treat adult and pediatric brain cancers with an FDA-approved modality known as Tumour Treating Fields (TTF), that has the greatest efficacy of any treatment. The single incumbent TTF product generates >\$0.5Bn in sales with limited market penetration due to a cumbersome design that limits uptake and efficacy. QV's proprietary device addresses these issues, and in preclinical testing our novel stimulation regimes outperform the incumbent by 3X. We are raising Series A to deliver a FIH clinical trial and access a TAM >\$30Bn across brain cancer indications.

qvbio.co.uk

Chris Bullock: chris@qvbio.co.uk



Reglagene, Houston, Texas

Reglagene is developing a novel drug, RGN6024, aimed at improving survival rates for patients with GBM and brain metastases originating from Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). These patients have limited therapeutic options and poor prognoses. Distinguishing RGN6024 from other therapies is its oral administration and brain penetration. The way it works is clinically validated, lessening development risk. In preclinical testing, RGN6024 significantly inhibits tumor growth and increases survival in animal models of human brain cancer and demonstrates an excellent safety profile that projects clinical utility.

reglagene.com

Richard Austin: austin@reglagene.com

The logo for RUA DIAGNOSTICS, featuring a stylized blue wave icon followed by the text "RUA DIAGNOSTICS" in a bold, uppercase, sans-serif font.

Rua Diagnostics, Westbury, New York

Rua is redefining point-of-care diagnostics with advanced micro gas chromatography (μ GC) technology for breath analysis, capable of detecting a wide range of prevalent and deadly diseases. Licensed from the University of Michigan, the platform delivers highly sensitive, software-generated results in just 30 minutes using an easy-to-operate device that requires no specialized training. Automated processing, AI/ML algorithms, and a cloud-based platform allow for remote updates, data cross-pollination and continuously expanding diagnostic capabilities. With a single sample, this non-invasive solution can diagnose multiple conditions, including infectious diseases, metabolic disorders, and cancers, making it a breakthrough in early disease detection and health monitoring.

ruadiagnostics.com

Jillian Levovitz: jillian@ruadiagnostics.com

PARTICIPATING COMPANIES



SolasCure, Cambridge, Cambridgeshire, United Kingdom

Chronic wounds cost the US >\$25 billion annually and significantly impact patients' quality of life. The first step in healing chronic wounds is debridement, however current 'gold standard' methods fall short and there is a huge unmet need for an easy-to-use, effective debridement product for use in the US and around the world. SolasCure is developing Aurase Wound Gel, a hydrogel containing the enzyme Tarumase which it originally identified in medical maggots, which debrides, reduces bacterial biofilm, and promotes healing. No other debridement treatment to date targets all elements of wound care management in a single product. Aurase Wound Gel has the potential to both improve the lives of millions of patients and also help address the immense economic burden caused by chronic wounds.

solascure.com

Lee Harle: lee@solascure.com



Somavac, Memphis, Tennessee

SOMAVAC is revolutionizing surgical wound care with its FDA-cleared, deep tissue negative pressure therapy system, enabling surgeons to remove drains 30% sooner. In addition, this active suction, closed-system therapy reduces the potential risk of infection while delighting patients by eliminating fluid handling. Currently targeting seroma prophylaxis in abdominal wall hernia and breast reconstruction, SOMAVAC is committed to transforming patient outcomes and elevating the standard of care in post-operative healing.

somavac.com

Elizabeth Hoff: elizabeth.hoff@somavac.com



Somnair, Towson, Maryland

Somnair is a pre-clinical stage medical device company with first-in-human and in-vivo animal evidence of our device's therapeutic efficacy in obstructive sleep apnea (OSA). OSA is a highly prevalent disease affecting 54 million Americans and 1 billion people worldwide. Untreated OSA doubles risk of heart attack, stroke and diabetes. Available treatments such as CPAP and implantable neurostimulation devices are uncomfortable, invasive, ineffective and abandoned by up to 50% of patients. Somnair is developing an entirely non-invasive neurostimulation oral appliance for the treatment of OSA, finally providing millions of patients with relief from this deadly disease.

somnairsleep.com

Anders Sideris: anders@somnairsleep.com



Taurus Vascular, Houston, Texas

Taurus Vascular is revolutionizing endovascular aneurysm repair (EVAR) by addressing the critical issues of residual aneurysm pressurization and endoleaks. Our innovative, catheter-deployable aortocaval shunt integrates effortlessly with any EVAR endograft, providing a pressure-relieving drainage pathway to accelerate aneurysm shrinkage and improve long-term outcomes. Taurus Vascular is dedicated to advancing vascular health with innovative, easy-to-implement technologies that elevate the effectiveness of aneurysm treatment and set a new standard for patient care.

taurusvascular.com

Matthew Kuhn: matt@taurusvascular.com

PARTICIPATING COMPANIES



Trueinvivo Ltd, Portsmouth, Hampshire, United Kingdom

TRUEinvivo develops and manufactures innovative radiation detection devices called DOSEmappers, using micro silica bead thermoluminescent detectors to precisely measure radiation received by cancer patients during radiotherapy. These patented devices improve treatment accuracy and reduce harm to healthy tissues by measuring radiation doses internally with unmatched precision. TRUEinvivo is also automating the production of DOSEmappers to enhance scalability and affordability. With regulatory approvals (CE and UKCA) and interest from leading institutions, TRUEinvivo aims to revolutionize radiotherapy by enabling personalized treatment adjustments, improving patient outcomes, and reducing long-term medical costs associated with unintended radiation exposure.

trueinvivo.co.uk

Shakardokht Jafari: shakardokht.jafari@trueinvivo.co.uk



Velvet Therapeutics

Velvet Therapeutics, Houston, Texas

Velvet Therapeutics is developing DNA-driven, non-viral in vivo cell therapies for oncology and autoimmune indications. Velvet's technology platform affords outsized therapeutic potential given its safety, targeted delivery, durability, redoseability, and cost.

velvettherapeutics.com

Chris Coker: chris.coker@velvettherapeutics.com



Voythos, Houston, Texas

Even with the staggering prevalence and morbidity of cardiovascular disease, existing tools only help expedite a diagnosis. Currently, there are no predictive toolsets for complex vascular disease, despite preventative treatments leading to the most cost-effective, highest-quality care. This is why we built Voythos. Voythos is a multimodal foundation model for predictive cardiovascular disease care. We Transform siloed clinical data and turn it into Hyper-specialized, disease-specific predictive models. Voythos' AI and platform enable a world with far better patient outcomes – all done for more people and more cost-effectively.

voythos.io

Sophia Khan: soph@voythos.io



YAP Therapeutics, Houston, Texas

YAP Therapeutics is an IND stage biotechnology company driving innovation for patients in the new field of tissue regeneration, antifibrosis and oncology. YAPtx develops genetic medicines and complex biologics that leverage the company's technology platforms to reverse and cure severe diseases, such as heart failure, pulmonary diseases, retinal degeneration and cancer.

yaptx.com

Tyler Kibbee: tkibbee@yaptx.com